A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
Incyte Corporation
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
University of Alabama at Birmingham
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Seagen Inc.
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic
Treeline Biosciences, Inc.
Kyowa Kirin Co., Ltd.
SciTech Development, Inc.
Ohio State University Comprehensive Cancer Center
Boston Immune Technologies and Therapeutics
Mayo Clinic
Thomas Jefferson University
City of Hope Medical Center
Tianjin Medical University Cancer Institute and Hospital
Fox Chase Cancer Center
City of Hope Medical Center
Kymera Therapeutics, Inc.
Bio-Path Holdings, Inc.
National Cancer Institute (NCI)
Daiichi Sankyo
Ohio State University Comprehensive Cancer Center
University of Pittsburgh
Mundipharma Research Limited
Pfizer
City of Hope Medical Center
Wake Forest University Health Sciences
Stanford University
Stanford University
Jiangsu Simcere Pharmaceutical Co., Ltd.
Karyopharm Therapeutics Inc
Genzada Pharmaceuticals USA, Inc.
Sorrento Therapeutics, Inc.
Jiangsu Simcere Pharmaceutical Co., Ltd.
National Institutes of Health Clinical Center (CC)
Codiak BioSciences
Peter MacCallum Cancer Centre, Australia
National Institutes of Health Clinical Center (CC)
University of Zurich
4SC AG
Fred Hutchinson Cancer Center
University of Michigan Rogel Cancer Center
Innate Pharma